Viropil 50/300/300mg Tablet

• Treatment of HIV infection

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.

Some common side effects of Viropil 50/300/300mg Tablet   include:

• Headache
• Fatigue
• Stomach Pain
• Increased Lipase Enzyme In Blood
• Loose And Watery Stools
• Dizziness
• Nausea

• The dosage and treatment duration of the Viropil 50/300/300mg Tablet are decided by the doctor according overall patient's health.
• This tablet should be taken with or without food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.​​
  

• Viropil 50/300/300mg Tablet is an antiviral medicine with the combination of Tenofovir, Disoproxil Lamivudine and Dolutegravir as an active ingredients.
• It works by preventing the multiplication of human immunodeficiency virus in human cells to stop the production of new viruses and clears up the infection from the body.​​
  

• Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A. (2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV, 7(10), e666-e676. https://pubmed.ncbi.nlm.nih.gov/33010240/
• Cattaneo, D., Capetti, A., & Rizzardini, G. (2019). Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opinion on Drug Metabolism & Toxicology, 15(3), 245-252. https://pubmed.ncbi.nlm.nih.gov/30704313/
• Paton, N. I., Musaazi, J., Kityo, C., Walimbwa, S., Hoppe, A., Balyegisawa, A., ... & Walker, S. (2022). Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. The Lancet HIV, 9(6), e381-e393. https://pubmed.ncbi.nlm.nih.gov/35460601/
• Venter, W. D., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., ... & Hill, A. (2019). Dolutegravir plus two different prodrugs of tenofovir to treat HIV. New England Journal of Medicine, 381(9), 803-815. https://pubmed.ncbi.nlm.nih.gov/31339677/
• Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., ... & Perea, R. T. (2019). Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet, 393(10167), 143-155.